Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2542479 | International Immunopharmacology | 2007 | 8 Pages |
Abstract
We investigated the bucillamine (Buc) mechanism inhibiting interleukin (IL)-1β-induced vascular endothelial growth factor (VEGF) production from human fibroblast-like synoviocytes (HFLS) which derived from the inflamed synovium of an RA patient using SA981, its active metabolite. HFLS did not produce IL-1β, spontaneously. While SA981 partially inhibited IL-1β-induced VEGF production at concentrations of 10 to 100 μM (10.1% and 14.2% inhibition of total VEGF production under IL-1β coexistence condition, respectively), it failed to inhibit IL-1β-induced IL-6 production at the same concentrations. IL-1β induced phosphorylation of the mitogen-activated protein (MAP) kinases, IκBα, c-Jun and Akt. SA981 at a concentration of 100 μM partially inhibited IL-1β-induced phosphorylation of p38MAPK and Akt (12.0% and 36.1% inhibition of each total amount of phosphoprotein under IL-1β coexistence condition, respectively). The VEGF promoter includes four transcription factors: AP1, hypoxia-inducible factor (HIF), Sp1 and AP2 binding elements. HIF-1β, Sp1 and AP1 increased under IL-1β coexistence conditions. At a concentration of 100 μM, SA981 attenuated increases in HIF-1β and Sp1 (10.1% and 19.8% inhibition of each total amount of transcription factor under IL-1β coexistence condition, respectively), but not AP1. These results suggest that SA981 partially inhibits VEGF production via modifications on IL-1β signaling. Attenuation of the expression of HIF-1β and Sp1 (but not AP1) may be a key with respect to SA981's selective inhibition of VEGF production.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Fumio Tsuji, Iwao Seki, Hiroyuki Aono, Noriko Odani, Keiko Mizutani, Masahiro Okamoto, Minoru Sasano,